appearing before the age of 65 was 65%h in the eastern region and 52 % in the south, compared with 31 % and 5 % respectively in brothers of healthy controls. These results suggest an apparent "ceiling effect," whereby the regional difference in CHD was almost obliterated among those with a positive family history. Conversely, the family history was much more ominous where the background risk was low: in this example the relative risk was about 6 in the south compared with only 1-3 in the high-risk eastern region.
How can we explain familial transmission? The main risk factors certainly run in families, partly through polygenic inheritance (factors such as blood pressure), rarely through the action of a single gene (familial hypercholesterolaemia), and in all cases additionally through a shared environment. Other investigators6 have concluded that aggregation of the known risk factors is only an incomplete explanation of the familial clustering of CHD, but the Finnish group disagree. They find very strong clustering of some major risk factors. For hyperlipoproteinaemia (mostly mixed) the relative risk was about 3 and for hypertension about 2, and the authors conclude that these factors accounted for most of the clustering of CHD. The implication is that (in Finland at least) a man with a family history of CHD has no increased risk unless he has a raised blood pressure or serum cholesterol concentration -or (particularly) both.
The extraordinarily high incidence of CHD in eastern Finland has always interested epidemiologists. The Seven Countries Study7 showed that it was to be expected from the high levels of risk factors which exist there, particularly the raised serum cholesterol concentrations. This new study extends this conclusion by showing that the big difference in incidence between the east and the south of Finland may again be accounted for by the east having twice the prevalence of hypertension and hyperlipoproteinaemia. We are glad to know that at least in Finland the familial and regional patterns of this disease seem to make sense. Clearly, knowledge of the normal anatomy of the recurrent laryngeal nerve is essential. In a careful study Wade'0 described eight anatomical variations in 100 thyroidectomies in the relation of the recurrent laryngeal nerve to the inferior thyroid artery: in 46% of cases the nerve was deep to the arterial trunk or its two divisions; in 10% it was superficial; while on the right side he identified no fewer than -four anomalous nerves. Extralaryngeal branching is not uncommon: in more than one-third of cases the nerve divides into two or more branches.2
The nerve may be damaged at the lower pole when it is included in the ligature of the inferior thyroid veins or at the upper pole during haemostasis of the thyroid remnant. In the middle third of its course fixation by the branches of the inferior thyroid artery or enclosure by a nodule places the nerve at risk. Gross displacement of the nerve is common in large retrostemal goitres, when delivery of the gland into the neck will present a risk of damage to the nerve unless all the inferior thyroid veins have been divided first and the retrosternal prolongation of the gland carefully mobilised, when the nerve can then be identified.
The hazard of damage to the nerve can best be avoided by exposing and identifying it. The surgeon may palpate the nerve (it feels like a cord) and identify its position to help in the exposure; he should see it fully and display its relation to the inferior thyroid artery and its branches. This should be sufficient in most cases, but in those in which a previous operation has been carried out or where the surgeon is still in doubt about the nerve's identity a battery-operated stimulator2 1 may be used to check the identity of the exposed nerve at operation. Folic acid is also lost in maintenance dialysis, and replacement of both this and iron is frequently required. The red blood cell membrane shows various transport abnormalities, mainly produced by humoral factors, and, though the decreased survival of red blood cells could be compensated for by a normal bone marrow, in chronic renal failure the marrow turnover is reduced.
Plasma erythropoietin concentrations are reduced or absent in anaemic uraemic patients, owing mainly to the reduction in functional renal mass.' Advanced renal disease also affects the endocrine as well as the secretory function ofthe kidneys,2 and, because plasma erythropoietin concentrations are difficult to measure accurately, we do not know whether there is also some impaired responsiveness to available erythropoietin or whether plasma inhibitors to erythropoietin are present.
Treatment ofthe anaemia ofrenal failure should theoretically be aimed at stimulating endogenous production of erythropoietin; increasing marrow responsiveness to it; or identifying and isolating a substance with erythropoietin-like properties.3 For years androgens have been known to increase the rate of erythropoiesis; to raise the plasma erythropoietin concentrations of both anaemic and non-anaemic patients with intact kidneys; and to raise the haemoglobin concentrations of patients with chronic renal failure. Their action may mainly depend on increasing erythropoietin production from remnants of the kidneys. Certainly, studies in animals suggest that extrarenal sites of erythropoietin production are relatively unresponsive to the action of androgens4-possibly an important factor in the timing of nephrectomy in patients on dialysis. Moreover, some drugs may also interfere with the action of testosterone. For example, its erythropoietic effect in female rats is almost completely abolished when these are pretreated with phenobarbitone5-a finding which if confirmed in man would have obvious practical importance.
Androgens have not been effective when used in patients with chronic renal failure not having maintenance dialysis. In those treated in this way, on the other hand, both the haemoglobin concentration and the packed cell volume (PCV) rose. This study was done in men given 300 mg testosterone propionate per week who still retained their kidneys, but no response occurred in anephric patients.6 Shaldon et a!7 reported an improvement in haemoglobin even in anephric patients, but they used a bigger dose oftestosterone (500 mg/week). Synthetic androgens have been used to try to avoid some of the complications of testosterone treatment. Nandrolone decanoate (Decadurabolin), which has to be given intramuscularly, was used in one double-blind trial, and raised both the haemoglobin concentration and the PCV.8 Oral synthetic androgens have also been tried. Eschbach and Adamson9 used fluoxymesterone with good haematological effect, though with less success in anephric patients; in a controlled trial oxymetholone failed to produce any benefit.10 Both these substances are C-17 methylated compounds, and may give rise to reversible liver damage, and will certainly make the patient more sensitive to concomitant warfarin treatment.
The other side effects of long-term androgen therapy may be important. Many men remark on improved sexual performance and increased muscle bulk, but priapism, occurring during sleep during dialysis, seems to be commoner and may result in permanent impotence. Problems in women include hirsutism, coarsening of the features, and acne. Haematomas are common at the injection site, especially since the injection is most conveniently given at the time of heparinisation for dialysis. Azotaemia may also suddenly increase after sudden withdrawal of androgens."1 Von Hartitzsch and his colleagues'2 have recently argued for controlled trials of androgens for the anaemia of renal failure. In the meantime they suggest that androgens should be prescribed selectively for anaemic men on regular haemodialysis-a reasonable summary of the small place of these drugs in chronic renal failure.
